-
By 2026, more than 25% of Eurobiomed’s member companies will be active in the digital health sector
-
Two events on April 9 and 14, 2024, in Toulouse and Montpellier to explore digital innovations in patient care pathways and their business models
Marseille, April 2 – Eurobiomed, a leading cluster for innovation and industrialization in the HealthTech sector in the South of France, is expanding its support for digital health companies.
Digital health: a rapidly growing sector within the healthcare industry
From online appointment scheduling to remote patient monitoring and medical decision-support tools, digital health is gradually transforming healthcare systems. In addition to these applications—which are still being adopted—there are disruptive innovations stemming from deep tech, such as artificial intelligence applied to medical imaging, digital patient twins, and digital therapies.
Digital health is emerging as one of the most dynamic sectors of the healthcare economy. Globally, the e-health market is projected to exceed $274 billion by 2025, with an annual growth rate of over 16% through 2030.[1] In France, the Ségur numérique program has already allocated up to 2 billion euros to accelerate the sector’s digital transformation.
Specific and complex market access challenges for e-health companies
Digital health companies face complex structural challenges because there are multiple pathways to market, and investors expect rapid and sustainable economic maturity. Rolling out an innovation therefore requires simultaneously winning over multiple stakeholders—including healthcare professionals, healthcare facilities, manufacturers, regulatory authorities, and payers—who have different expectations and timelines.
In this context, Eurobiomed’s support for companies is a key factor in securing and accelerating their market access. Initially, this involves advising them on potential marketing channels for their products (reimbursement by health insurance, hospital purchases, industrial partnerships, or direct payment by patients or healthcare professionals), and explaining the decision-making processes and purchasing patterns within the hospital sector.
Eurobiomed: Comprehensive support at every key stage of development
Of Eurobiomed’s 430 members in Occitanie and the Sud region, more than 100 companies operate in the digital health sector: 45 members develop medical solutions, 14 specialize in patient support, and 25 design organizational tools as well as solutions for payers and preventive care. For these companies, Eurobiomed is involved at every critical stage of their development:
- Identifying and securing public funding (innovation grants, calls for proposals)
- Designing business models (identifying target markets, buyers, and payers)
- Regulatory support and market access through its network of experts
- Facilitating the ecosystem, sharing best practices, and connecting key stakeholders
“Sêmeia is a perfect example of the value of our e-health support. Sêmeia is developing a digital medical device capable of continuously analyzing patients’ health data (blood pressure, biological parameters, body mass index) to help doctors adjust treatments remotely. “We supported the company in structuring its business model, identifying funding opportunities, and connecting with clinical partners to ensure the success of its validation phases and accelerate its market entry,” explains Emilie Royère, Managing Director of Eurobiomed.
Two events to shed light on the key issues facing the industry
In this context, Eurobiomed is organizing two key events in April to provide practical insights and foster dialogue among industry stakeholders.
Through an immersive experience at Clinique Pasteur—a facility recognized for its leadership in digitizing patient care pathways and its active role in testing innovative solutions—this event aims to provide a concrete illustration of how innovations are integrated into medical practice. The facility will share its experience alongside two Eurobiomed member companies: Inseparable, which strengthens the bond between healthcare providers, patients, and family members during hospitalization, and KanopyMed, which specializes in predictive analysis of health data using artificial intelligence.
As part of the C-Level Executives Forum, this event brings together an investor and industry leaders to share practical insights on market access strategies and to compare and contrast the various development models in digital health.
Speakers will include Mathieu Trystram (Caisse des Dépôts), Emilie Mercadal (Rofim), and Pierre Hornus (Séméa).
About Eurobiomed
Eurobiomed is the leading cluster for innovation and industrialization in the HealthTech sector in southern France. It brings together more than 430 stakeholders, companies, research institutions, clinical, industrial, and institutional players in Occitanie and the South regions—Provence-Alpes-Côte-d'Azur and Occitanie/Pyrénées-Méditerranée.
Eurobiomed supports HealthTech companies at every stage of their development, from research to commercialization, and facilitates qualified connections with key players in the healthcare ecosystem (university hospitals, technology platforms, manufacturers, financiers, investors). By structuring sectors and scaling up innovations, Eurobiomed helps to strengthen the sovereignty and competitiveness of French HealthTech.
Press Contacts
Agence NewCap
Nicolas Merigeau
+33 (0)1 44 71 94 98
Gaëlle Fromaigeat
+33 (0)6 58 16 33 76
